Company intelligence / Profile preview

ARCALIS

Minamisoma, Fukushima, Japancorp.arcalis.co.jp ↗

Ownership: Private
Development stage: Commercial

Overview

ARCALIS operates state-of-the-art cGMP facilities for the development and manufacture of mRNA vaccines and therapeutics. It provides end-to-end services from early development through commercial production. The company has received significant Japanese government funding to expand capacity and is positioned as one of the most advanced global CDMOs specializing in mRNA/LNP medicines[1][3][8].

Modalities: mRNA-based drugsLipid nanoparticle delivery therapySelf-amplifying mRNA-based drugs
Industry: Contract Manufacturing Organization

Partnerships

AxceleadArcturus TherapeuticsMeiji Seika PharmaCSL Seqirus

Beyond the preview

Go deeper on ARCALIS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARCALIS.

Explore the full profile